NWOG

Northwest Biotherapeutics is a clinical-stage biotechnology company developing personalized immune therapies for cancer. The company's proprietary DCVax platform utilizes a patient's own dendritic cells to trigger a broad immune response against their specific tumor antigens. Its lead product candidate, DCVax-L, has completed a large Phase 3 clinical trial for glioblastoma multiforme, showing a significant extension in overall survival for both newly diagnosed and recurrent patients. The company is also advancing DCVax-Direct for inoperable solid tumors and DCVax-Prostate for late-stage prostate cancer. Northwest Biotherapeutics operates a specialized manufacturing facility in the United Kingdom to support its clinical and future commercial operations.